Cargando…

ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy

BACKGROUND: Polymorphisms in the excision repair cross-complimentary group 1 (ERCC1) gene have been involved in the prognosis of various cancers. In the present study, we evaluated the prognostic role of the two most common ERCC1 polymorphisms in patients with T4 breast cancer receiving platinum-bas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palomba, Grazia, Atzori, Francesco, Budroni, Mario, Ombra, MariaNeve, Cossu, Antonio, Sini, MariaCristina, Pusceddu, Valeria, Massidda, Bruno, Frau, Barbara, Notari, Francesca, Ionta, MariaTeresa, Palmieri, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177579/ https://www.ncbi.nlm.nih.gov/pubmed/25253066 http://dx.doi.org/10.1186/s12967-014-0272-4

Ejemplares similares

Molecular alterations in key-regulator genes among patients with T4 breast carcinoma
por: Massidda, Bruno, et al.
Publicado: (2010)

Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets
por: Palmieri, Giuseppe, et al.
Publicado: (2015)

Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia
por: PALOMBA, GRAZIA, et al.
Publicado: (2014)

Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia
por: Palomba, Grazia, et al.
Publicado: (2012)

Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy
por: Casula, Milena, et al.
Publicado: (2009)

Dietary compounds and cutaneous malignant melanoma: recent advances from a biological perspective
por: Ombra, Maria Neve, et al.
Publicado: (2019)

Origin and distribution of the BRCA2-8765delAG mutation in breast cancer
por: Palomba, Grazia, et al.
Publicado: (2007)

Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma
por: Palomba, Grazia, et al.
Publicado: (2016)

Vitamin D status and risk for malignant cutaneous melanoma: recent advances
por: Ombra, Maria N., et al.
Publicado: (2017)

Study of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers
por: Abyarghamsari, Mahdiye, et al.
Publicado: (2019)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

Nestin expression associates with poor prognosis and triple negative phenotype in locally advanced (T4) breast cancer
por: Piras, F., et al.
Publicado: (2011)

ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy
por: Baiomy, Mohamed Ali EL, et al.
Publicado: (2017)

Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy
por: Pongmaneratanakul, Skolchart, et al.
Publicado: (2017)

Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia
por: Budroni, Mario, et al.
Publicado: (2009)

Primary Dermal Melanoma in a Patient with a History of Multiple Malignancies: A Case Report with Molecular Characterization
por: Sini, Germana, et al.
Publicado: (2013)

Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
por: Tang, Ning, et al.
Publicado: (2017)

KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors
por: Palomba, Grazia, et al.
Publicado: (2020)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

A common polymorphism in the 5′ UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy
por: Somers, Joanna, et al.
Publicado: (2015)

Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy
por: Yamashita, Fumie, et al.
Publicado: (2013)

Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population
por: Wu, Xiaoqing, et al.
Publicado: (2023)

Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study
por: Paliogiannis, Panagiotis, et al.
Publicado: (2022)

KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma
por: PALIOGIANNIS, PANAGIOTIS, et al.
Publicado: (2014)

ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy
por: Ryu, Hyewon, et al.
Publicado: (2017)

Chinese C allele carriers of the ERCC5 rs1047768 polymorphism are more sensitive to platinum-based chemotherapy: a meta-analysis
por: Xu, Meizhen, et al.
Publicado: (2017)

The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy
por: Wahba, Nagwa Ismail, et al.
Publicado: (2023)

Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
por: Palomba, Grazia, et al.
Publicado: (2016)

ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
por: Wang, Xiyong, et al.
Publicado: (2017)

ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy
por: Liblab, Salisa, et al.
Publicado: (2020)

A miR‐15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum‐based chemotherapy
por: Xue, Ping, et al.
Publicado: (2022)

Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts
por: Guffanti, Federica, et al.
Publicado: (2020)

High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer
por: Du, Pei, et al.
Publicado: (2016)

Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach
por: Manca, Antonella, et al.
Publicado: (2019)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
por: Manca, Antonella, et al.
Publicado: (2015)

ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy
por: Xian-jun, Feng, et al.
Publicado: (2014)

Effect of the ERCC1 (C118T) Polymorphism on Treatment Response in Advanced Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy
por: Kaewbubpa, Walennee, et al.
Publicado: (2016)

Genetic polymorphisms of ERCC-1 and ERCC-2 are not prognostic markers in osteosarcoma patients with chemotherapy: A meta-analysis in Chinese population
por: Liu, Dabiao, et al.
Publicado: (2018)

Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients
por: Colombino, Maria, et al.
Publicado: (2020)

Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer
por: Li, Guoping, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1e4bp7hqf6n7me18e3mghinhf5